Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double‐blind, placebo‐controlled Phase 2 trial
Clinical and Translational Medicine2022Vol. 12(5), pp. e790–e790
Citations Over TimeTop 10% of 2022 papers
Anne Weiss, Emilie Delavenne, Carina Matias, Heimo Lagler, Daniel Simon, Ping Li, Jon Hansen, Teresa Pires dos Santos, Bimal Jana, Petra A. Priemel, Christine Bangert, Martin Bauer, Sabine Eberl, Alina Nussbaumer‐Pröll, Zoe Österreicher, Peter Matzneller, Tamara Quint, Maria Weber, Hanne Mørck Nielsen, Thomas Rades, Helle Krogh Johansen, Henrik Westh, Wooseong Kim, Eleftherios Mylonakis, Christian Friis, Luca Guardabassi, John Pace, Carina Vingsbo Lundberg, Fatima M’Zali, Pascal Butty, Nikolaj Sørensen, Henrik Bjørn Nielsen, Rasmus Toft‐Kehler, Emma Guttman‐Yassky, Georg Stingl, Markus Zeitlinger, Morten Otto Alexander Sommer
Abstract
These results suggest that ATx201 could become a new treatment modality as a decolonizing agent.
Related Papers
- → Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis(2017)1,056 cited
- → The Cotton Rat as a Model for Staphylococcus aureus 19 Nasal Colonization in Humans(2008)31 cited
- → Virulence Gene Expression of Staphylococcus aureus in Human Skin(2021)27 cited
- → The Skin Microbiome in Atopic Dermatitis and Its Relationship to Emollients(2015)32 cited
- → Altered Maturation of the Skin Microbiome in Infants with Atopic Dermatitis(2022)5 cited